365270Curacle365270 info
$4.13info-0.36%24h
Global rank24430
Market cap$57.24M
Change 7d-11.04%
YTD Performance-53.87%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Curacle (365270) Stock Overview

    Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company's products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial. Its products in back-up pipeline include CU02, a product for nonalcoholic steatohepatitis treatment; CU04, a product for the treatment of cancer (c-Myc inhibitor); and CU05, a product for the treatment of cancer (Amigo2-PDK1 inhibitor). The company was founded in 2016 and is based in Seongnam, South Korea.

    365270 Stock Information

    Symbol
    365270
    Address
    Ga dong #608~611Seongnam, South Korea
    Founded
    -
    Trading hours
    -
    Website
    https://curacle.com
    Country
    πŸ‡°πŸ‡· South Korea
    Phone Number
    82 3 1706 8300

    Curacle (365270) Price Chart

    -
    Value:-

    Curacle Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $4.13
    N/A
    Market Cap
    $57.24M
    N/A
    Shares Outstanding
    13.86M
    N/A
    Employees
    0
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org